医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

iMDsoft launches new version of the MetaVision Clinical Information System

2014年09月15日 PM05:02
このエントリーをはてなブックマークに追加


 

DÜSSELDORF, Germany

iMDsoft® announced the release of a new version of its clinical information system, MetaVision 6. Based on the latest technology, this release introduces new functionality designed to increase patient safety, such as advanced electronic medication management and multi-patient views. MetaVision’s updated graphical user interface makes for an intuitive user experience, enabling faster navigation between patients and fewer clicks. System improvements deliver better performance, reduced latency and improved scalability. The new version enables iMDsoft to expand its clinical solutions hospital-wide, helping prevent patient deterioration, costly complications and readmission to the ICU.

MetaVision is designed to deliver results in areas of the hospital with the highest cost, morbidity, mortality and revenue. The system offers workflow coverage across the entire continuum of care, maintaining a single patient record throughout ICUs, pre-op units, ORs, recovery units and general floors.

MetaVision generates complete and accurate electronic medical records, offering minute-by-minute patient data collection and display. Advanced decision support options promote the delivery of best practices, protocols, and regulatory requirements.

iMDsoft is proud to offer new features supporting the full medication cycle: ordering, preparation, and administration. Safety checks via barcode scanning ensure that all medication orders are correct. Synchronisation with third-party drug libraries streamlines prescribing and enhances clinical decision support. Drug costs are controlled by ensuring the use of hospital preferred products.

Multi-patient management makes it easier for clinicians to ensure patient safety and work more effectively. Clinicians identify which patients need attention first with a panoramic overview of all the patients under their care. Caregivers from any department can see any subset of patients at a glance.

iMDsoft is constantly looking for new ways to leverage MetaVision’s unique capabilities, and to offer the widest number of patients the best possible care. Designed to deliver efficient software deployments across multiple sites, MetaVision has become the clinical information system of choice for governments and health networks, with a successful track record of regional projects worldwide.

“This release embodies two of our core values: close cooperation with the MetaVision user community and commitment to innovation,” said Lars-Oluf Nielsen, CEO of iMDsoft. “iMDsoft is focused on helping our partners maintain the highest level of care while responding to growing demands for increased efficiency. MetaVision 6 reflects our desire to meet our customer’s changing needs and our determination to stay at the forefront of our field.”

The solution will be demonstrated at the ESICM Annual Congress in Barcelona, September 27-October 01, and at the ANZICS/ACCCN ASM 2014 in Melbourne, October 09-11.

About iMDsoft

iMDsoft is a leading provider of Clinical Information Systems for critical, perioperative, and acute care environments. The company’s flagship family of solutions, the MetaVision Suite, was first implemented in 1999. MetaVision generates comprehensive and accurate electronic medical records, and offers advanced decision support and medication management. Hospitals worldwide use MetaVision to improve care quality and enhance financial results. The system promotes compliance with protocols and best practices, streamlines reporting and supports clinical research. To learn more about iMDsoft, visit www.imd-soft.com.

CONTACT

iMDsoft
Anne Belkin, +781-4495567
Director of Marketing
anne.belkin@imd-soft.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表